Lawmakers eye pricing

Share this article:

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers—Novartis's Alcon division, Johnson & Johnson and Valeant's Bausch + Lomb unit—decided to set minimum prices for prescription contacts. Reuters reports that the committee will determine if the minimum prices harm consumers.

The newswire notes that setting a minimum price has been legal since a 2007 Supreme Court ruling said such a move is OK, but antitrust experts tell Reuters that manufacturers may have set minimums as a way to prompt optometrists to write prescriptions for their brand.

Novartis tells Reuters it decided to go with a minimum retail price to keep patients from pumping doctors for product information only to purchase contacts online at lower prices.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.